UroGen Pharma Appoints New CMO, Elects Directors
Ticker: URGN · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $36,260, $217,590, $500,000, $13.11 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
UroGen shakes up leadership: new CMO, two new board members appointed.
AI Summary
UroGen Pharma Ltd. announced on October 7, 2024, the appointment of Dr. Anup Rampersaud as Chief Medical Officer and the election of Ms. Sarah O'Connor and Mr. David E.I. Johnson to its Board of Directors. The company also reported on compensatory arrangements for its officers.
Why It Matters
These executive and board changes could signal shifts in UroGen's strategic direction and leadership, potentially impacting its drug development and commercialization efforts.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- Dr. Anup Rampersaud (person) — Appointed Chief Medical Officer
- Ms. Sarah O'Connor (person) — Elected to Board of Directors
- Mr. David E.I. Johnson (person) — Elected to Board of Directors
- October 7, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of UroGen Pharma Ltd.?
Dr. Anup Rampersaud has been appointed as the new Chief Medical Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 7, 2024.
Who were elected to the Board of Directors of UroGen Pharma Ltd.?
Ms. Sarah O'Connor and Mr. David E.I. Johnson were elected to the Board of Directors.
What other information is disclosed regarding compensatory arrangements?
The filing indicates that compensatory arrangements of certain officers are also being reported.
What is the principal executive office address for UroGen Pharma Ltd.?
The address of the principal executive offices is 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540.
Filing Stats: 1,590 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-10-09 08:18:29
Key Financial Figures
- $36,260 — iod") in exchange for a cash payment of $36,260. Mr. Kim's outstanding equity awards as
- $217,590 — onths, (ii) a lump sum payment equal to $217,590, which is equal to Mr. Kim's target per
- $500,000 — led to an initial annual base salary of $500,000. Mr. Degnan is also eligible to receive
- $13.11 — lue NIS 0.01, with an exercise price of $13.11 (the "Option"), and (ii) 13,450 restric
Filing Documents
- d838231d8k.htm (8-K) — 34KB
- d838231dex101.htm (EX-10.1) — 40KB
- d838231dex102.htm (EX-10.2) — 43KB
- 0001193125-24-234808.txt ( ) — 269KB
- urgn-20241007.xsd (EX-101.SCH) — 3KB
- urgn-20241007_lab.xml (EX-101.LAB) — 18KB
- urgn-20241007_pre.xml (EX-101.PRE) — 11KB
- d838231d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 10.1 Separation Agreement between the Company and Don Kim, dated October 7, 2024. 10.2 Employment Agreement between the Company and Christopher Degnan, dated October 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2024 UROGEN PHARMA LTD. By: /s/ Elizabeth Barrett Elizabeth Barrett President and Chief Executive Officer